Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non-Hodgkin Lymphoma Treatment Landscape. Click here to read more @ Non-Hodgkin Lymphoma Pipeline Outlook
Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report
In June 2025, AstraZeneca announced a study is designed to evaluate the safety, tolerability, PK, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
In June 2025, Genmab conducted a study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.
In June 2025, Artiva Biotherapeutics Inc. organized clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients.
DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
The leading Non-Hodgkin Lymphoma Companies such as Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others.
Discover groundbreaking developments in Non-Hodgkin Lymphoma Therapies! Gain in-depth knowledge of key Non-Hodgkin Lymphoma clinical trials, emerging drugs, and market opportunities @ Non-Hodgkin Lymphoma Clinical Trials Assessment
Non-Hodgkin Lymphoma Emerging Drugs Profile
Golcadomide: Bristol Myers Squibb
Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma.
MEN 1703: Ryvu Therapeutics
MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
LP-168: Guangzhou Lupeng Pharmaceutical
LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
DR-0201: Dren Bio
DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem's novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma.
The Non-Hodgkin Lymphoma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment.
Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market
Stay informed about the Non-Hodgkin Lymphoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Non-Hodgkin Lymphoma Unmet Needs
Non-Hodgkin Lymphoma Companies
Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Transform your understanding of the Non-Hodgkin Lymphoma Pipeline! See the latest progress in drug development and clinical research @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Non-Hodgkin Lymphoma Pipeline Report
Coverage- Global
Non-Hodgkin Lymphoma Companies- Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others.
Non-Hodgkin Lymphoma Pipeline Therapies- Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others.
Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Non-Hodgkin Lymphoma Pipeline Analysis Today! @ Non-Hodgkin Lymphoma Drugs and Companies
Table of Contents
Introduction
Executive Summary
Non-Hodgkin Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Non-Hodgkin Lymphoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Golcadomide: Bristol Myers Squibb
Mid Stage Products (Phase II)
MEN 1703: Ryvu Therapeutics
Early Stage Products (Phase I)
DR-0201: Dren Bio
Preclinical and Discovery Stage Products
ETR-7072: EntreChem
Inactive Products
Non-Hodgkin Lymphoma Key Companies
Non-Hodgkin Lymphoma Key Products
Non-Hodgkin Lymphoma- Unmet Needs
Non-Hodgkin Lymphoma- Market Drivers and Barriers
Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
Non-Hodgkin Lymphoma Analyst Views
Non-Hodgkin Lymphoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Market Analysis: July 1st, 2025
Global Markets American Markets U.S. stocks traded Tuesday mixed as investor sentiment remained cautious amid growing concerns about the country's fiscal outlook. Federal Reserve Chair Jerome Powell hinted at the possibility of a rate cut as early as July, a signal that followed mounting political pressure from former President Donald Trump, who has been critical of the prolonged period of elevated interest rates. While markets typically welcome dovish signals from the Fed, uncertainty about long-term fiscal policy continues to weigh on investor confidence. European Markets In Europe, markets traded broadly lower, as the euro strengthened, reflecting confidence in the region's economic fundamentals, according to the European Central Bank. The ECB's Christine Lagrade, commented that the appreciation of the currency is consistent with underlying economic resilience. Tesla reported higher sales for June in Spain, Portugal, and Norway, however France saw a 10% decline. Stellantis warned it may be forced to shut down some factories due to potential fines from the European Union over carbon emissions. This underscores the rising regulatory pressure on automakers as the EU tightens its climate targets. In the UK, stocks moved higher, buoyed by strong corporate news. Pharmaceutical giant AstraZeneca is reportedly considering moving its stock listing to a U.S. exchange, a move that would signals general growing dissatisfaction with the London market's limited liquidity and valuation discounts compared to U.S. peers. Spanish lender Santander announced a £2.65 billion acquisition of UK-based TSB Bank, fueling concerns over branch closures and potential job losses. Corporate News Alphabet Inc:OpenAI denied using Google's proprietary AI chips despite reports of collaboration via Google Cloud and plans to warn EU regulators that antitrust rules may hinder innovation. Apple Inc:Brazil's antitrust body recommended penalties against Apple for anti-competitive practices in its iOS ecosystem, prompting the company to raise privacy and user experience concerns. Boeing Co:Boeing appointed former Lockheed Martin executive Jay Malave as CFO, signaling a broader leadership shake-up under CEO Kelly Ortberg. Carvana Co:Jefferies raised Carvana's price target to $325, expecting accelerated retail growth amid rising demand. Circle Internet Group Inc:Circle is seeking a U.S. national trust bank charter to directly manage USDC reserves and offer tokenized asset custody services to institutions. Citigroup Inc Citigroup appointed Akira Kiyota and Taiji Nagasaka to lead investment banking in Japan, highlighting efforts to expand amid growing M&A activity. Cloudflare Inc:Cloudflare launched a tool enabling websites to block or monetize AI bot access, offering publishers more control over their content. Equinor ASA:Equinor and partners approved a $1.29 billion expansion of the Johan Sverdrup oilfield to increase output by up to 50 million barrels. First Citizens Bancshares Inc:JPMorgan raised First Citizens' target price to $2,250, citing strength in its SVB division and potential long-term deposit growth. Hershey Co:Hershey will remove synthetic dyes from its snacks by 2027 to align with evolving U.S. health regulations. INmune Bio Inc:Scotiabank downgraded INmune Bio after its lead Alzheimer's drug failed a Phase 2 trial, slashing the price target to $0.60. Joby Aviation Inc:Joby completed a successful electric air taxi test flight in Dubai, advancing the city's vision for urban aerial mobility. Morgan Stanley:Morgan Stanley led a $10 billion capital raise for Elon Musk's xAI to fund AI infrastructure and development of the Grok platform. Oracle Corp:TD Cowen raised Oracle's target price to $250 on the back of new large cloud service agreements expected to lift revenue. Wolfspeed Inc:Wolfspeed filed for Chapter 11 bankruptcy to restructure nearly $4.6 billion in debt amid slumping chip demand and macro headwinds. Zions Bancorporation:JPMorgan increased Zions' price target to $55, citing its strong position in lending to small and mid-sized businesses.
Globe and Mail
8 hours ago
- Globe and Mail
Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Non-Hodgkin Lymphoma Pipeline Insight, 2025 ' report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non-Hodgkin Lymphoma Treatment Landscape. Click here to read more @ Non-Hodgkin Lymphoma Pipeline Outlook Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report In June 2025, AstraZeneca announced a study is designed to evaluate the safety, tolerability, PK, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies. In June 2025, Genmab conducted a study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. In June 2025, Artiva Biotherapeutics Inc. organized clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment. The leading Non-Hodgkin Lymphoma Companies such as Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others. Discover groundbreaking developments in Non-Hodgkin Lymphoma Therapies! Gain in-depth knowledge of key Non-Hodgkin Lymphoma clinical trials, emerging drugs, and market opportunities @ Non-Hodgkin Lymphoma Clinical Trials Assessment Non-Hodgkin Lymphoma Emerging Drugs Profile Golcadomide: Bristol Myers Squibb Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma. MEN 1703: Ryvu Therapeutics MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. LP-168: Guangzhou Lupeng Pharmaceutical LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. DR-0201: Dren Bio DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem's novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. The Non-Hodgkin Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment. Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market Stay informed about the Non-Hodgkin Lymphoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Non-Hodgkin Lymphoma Unmet Needs Non-Hodgkin Lymphoma Companies Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Transform your understanding of the Non-Hodgkin Lymphoma Pipeline! See the latest progress in drug development and clinical research @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Non-Hodgkin Lymphoma Pipeline Report Coverage- Global Non-Hodgkin Lymphoma Companies- Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Non-Hodgkin Lymphoma Pipeline Therapies- Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others. Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Non-Hodgkin Lymphoma Pipeline Analysis Today! @ Non-Hodgkin Lymphoma Drugs and Companies Table of Contents Introduction Executive Summary Non-Hodgkin Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Non-Hodgkin Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Golcadomide: Bristol Myers Squibb Mid Stage Products (Phase II) MEN 1703: Ryvu Therapeutics Early Stage Products (Phase I) DR-0201: Dren Bio Preclinical and Discovery Stage Products ETR-7072: EntreChem Inactive Products Non-Hodgkin Lymphoma Key Companies Non-Hodgkin Lymphoma Key Products Non-Hodgkin Lymphoma- Unmet Needs Non-Hodgkin Lymphoma- Market Drivers and Barriers Non-Hodgkin Lymphoma- Future Perspectives and Conclusion Non-Hodgkin Lymphoma Analyst Views Non-Hodgkin Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CBC
9 hours ago
- CBC
Non-profit run by 23andMe co-founder gets court approval to buy the genetic testing company
Social Sharing Anne Wojcicki's bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court green light. That means Wojcicki's non-profit TTAM Research Institute will purchase "substantially all" of San Francisco-based 23andMe's assets for $305 million US (about $416 million Cdn). The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. "I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said in a statement Monday. She later added that, "the future of health care belongs to all of us." The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a months-long bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for $256 million US in May. But Wojcicki's non-profit later topped that offer, winning the final round of bidding held last month. Under the deal, TTAM will acquire 23andMe's signature "Personal Genome Service" provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavour proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a "clear" difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be "in the best position" as an independent bidder. Now that Wojcicki's non-profit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process, notably with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. WATCH | 23andMe customers urged to delete personal data: 23andMe customers urged to delete personal data 3 months ago Duration 1:44 Roughly 15 million customers who used the genetic testing company 23andMe are being urged to take steps to delete their personal data and protect their privacy. Cybersecurity experts say that DNA data could be sold as part of a restructuring or sale after the company filed for bankruptcy protection. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah "remain actively opposed to the sale." In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale "does not comply" with genetic privacy law in the state — and said it was "disappointed" with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office for further comment on Tuesday. When announcing its intended sale to Wojcicki's non-profit last month, 23andMe confirmed that TTAM "has affirmed its commitment" to comply with the company privacy policies and applicable law. That means TTAM will honour existing policies around consumer data, the company said, which includes allowing users to delete their data and "opt out" of research. All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki said: "Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish."
